HomeAI · summaries
Storia in 6 fonti
Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks
By acquiring Crinetics Pharmaceuticals, Vertex is staking its place alongside other big biotechs such as Gilead, Regeneron and Biogen.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
markets.businessinsider.com
M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition
Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceut...
- ·
endpoints.news
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and endocrinology pipeline with ~$5B peak sales potential.
- ·
benzinga.com
Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why - Crinetics Pharmaceuticals (NASDAQ:C
Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the company announced it will be acquired by Vertex.
- ·
statnews.com
Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies announced.
- ·
biopharmadive.com
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.
- ·
fiercepharma.com
Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire | Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire endocrine…
- ·
Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets - Vertex Pharmaceuticals (NASDAQ:V
Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to its rare disease portfolio.
- ·
Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder
- ·
Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks
By acquiring Crinetics Pharmaceuticals, Vertex is staking its place alongside other big biotechs such as Gilead, Regeneron and Biogen.